Invesco
CNCE

Invesco’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Invesco’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-237,277
Closed -$1.59M – 4082
2022
Q3 		$1.59M Buy
+237,277
New +$1.44M ﹤0.01% 2736
2021
Q1 		– Sell
-16,399
Closed -$207K – 3973
2020
Q4 		$207K Buy
16,399
+3,037
+23% +$34.6K ﹤0.01% 3526
2020
Q3 		$131K Sell
13,362
-58,486
-81% -$576K ﹤0.01% 3550
2020
Q2 		$714K Sell
71,848
-3,233
-4% -$31K ﹤0.01% 2972
2020
Q1 		$664K Buy
75,081
+58,310
+348% +$575K ﹤0.01% 2938
2019
Q4 		$155K Sell
16,771
-1,102
-6% -$7.81K ﹤0.01% 3568
2019
Q3 		$105K Sell
17,873
-696
-4% -$7.38K ﹤0.01% 3625
2019
Q2 		$223K Sell
18,569
-5,541
-23% -$59.6K ﹤0.01% 3592
2019
Q1 		$291K Buy
+24,110
New +$355K ﹤0.01% 3498
2018
Q4 		– Sell
-41,587
Closed -$617K – 3895
2018
Q3 		$617K Sell
41,587
-11,471
-22% -$180K ﹤0.01% 3344
2018
Q2 		$893K Sell
53,058
-105,484
-67% -$2.05M ﹤0.01% 3192
2018
Q1 		$3.63M Buy
158,542
+109,255
+222% +$2.43M ﹤0.01% 2159
2017
Q4 		$1.27M Buy
49,287
+31,890
+183% +$642K ﹤0.01% 2884
2017
Q3 		$257K Sell
17,397
-101,787
-85% -$1.48M ﹤0.01% 3495
2017
Q2 		$1.66M Buy
119,184
+63,094
+112% +$930K ﹤0.01% 2704
2017
Q1 		$957K Buy
56,090
+216
+0.4% +$2.59K ﹤0.01% 3052
2016
Q4 		$575K Sell
55,874
-22,971
-29% -$210K ﹤0.01% 3244
2016
Q3 		$796K Buy
78,845
+851
+1% +$9.3K ﹤0.01% 3067
2016
Q2 		$876K Sell
77,994
-24,146
-24% -$307K ﹤0.01% 2972
2016
Q1 		$1.4M Sell
102,140
-15,975
-14% -$230K ﹤0.01% 2705
2015
Q4 		$2.24M Buy
118,115
+10,696
+10% +$232K ﹤0.01% 2453
2015
Q3 		$2.02M Buy
107,419
+107,064
+30,159% +$1.82M ﹤0.01% 2507
2015
Q2 		$5K Buy
+355
New +$5.41K ﹤0.01% 4235

Other funds holding CNCE

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco's CNCE Position: Q4 2022 in Review

Invesco sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2022, closing a stake of 237,277 shares — an estimated $1.59M sold.

Invesco first reported a position in CNCE in Q2 2015 and held it in 23 quarters. The position peaked at $3.63M in Q1 2018. 85 funds tracked by Wall St. Rank hold CNCE as of Q4 2022.

  • Invesco reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Invesco sold 237,277 Concert Pharmaceuticals, Inc. shares in Q4 2022, an estimated $1.59M.
  • Invesco first reported a position in Concert Pharmaceuticals, Inc. in Q2 2015 and held it in 23 quarters.
  • Invesco's Concert Pharmaceuticals, Inc. position peaked at $3.63M in Q1 2018.
  • 85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2022.

Based on Invesco's 13F filing for Q4 2022, filed 13 Feb 2023.